Goldline Pharmaceutical Limited, established on August 2, 2004, initially operated as a private limited company before transitioning to a public limited entity in 2013. The company is dedicated to the marketing of pharmaceutical products under its flagship "Goldline" brand. Its product portfolio is segmented into five categories: Goldline Pharma, Goldline Cardinal, Goldline Aayushman, Goldline InLife, and Goldline Valiente. Notably, Goldline does not engage in direct manufacturing, instead relying on contractual arrangements with 15 third-party manufacturers to produce its products based on market research, demand analysis, and specified requirements.
The company operates a well-structured supply chain, supported by partnerships with seven distributors. Additionally, Goldline extends material supply and procurement support to hospitals and healthcare providers. It leverages its promoter group entities, Numerius Healthcare Pvt Ltd and Activista Healthcare Pvt Ltd, to effectively manage trading operations, streamline distribution, and ensure logistical efficiency, solidifying its position in the pharmaceutical supply chain.
Goldline Pharmaceutical Limited is preparing for an Initial Public Offering (IPO) by issuing 30,00,000 equity shares with a face value of Rs. 10 each as part of a fresh issue. Prospective investors should note the company's strong focus on marketing and supply chain efficiency, as well as its dependence on third-party manufacturers, which could provide both opportunities and challenges for scalability and profitability.